Michal Sheffer

#bioinformatics #cancer #immunotherapy #CRISPR
computational biologist

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Eradicating Drug Tolerant Persister Cells in EGFR-Mutated NSCLC by Targeting TROP2 with CAR-T Cellular Therapy - by Simon Baldacci, @EJBrea, Francesco Facchinetti, @ESmithMDPhD, Pasi Jänne, @DavidBarbie8, and colleagues https://t.co/psE0fK7kPz @DanaFarber

[Dana-Farber News @DanaFarberNews]

Congratulations to Eric Smith, MD, PhD, @DanaFarber on receiving the Outstanding New Investigator Award from @ASGCTherapy. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025

[Dana-Farber News @DanaFarberNews]

We’re getting ready to wrap up #AACR25 today, but not before congratulating @DanaFarber's Matthew Meyerson, MD, PhD, FAACR, @DrChoueiri and Alice T. Shaw, MD, PhD, once again for receiving @AACR 2025 Scientific Achievement Awards. @DanaFarber

➡️ https://t.co/eJzRT7DvnC

[Michal Sheffer @MichalSheffer]

I am honored to talk at the next BDDI meeting,
Thank you for inviting me!

[Kristopher Sarosiek @CellDeathLab]

➡️Join our next BCDI meeting for exciting discussions on programmed cell removal from @mounicav07 @broadinstitute and NK-mediated targeting of tumor cells from @MichalSheffer @DanaFarber! Monday April 7th at 3PM on the Harvard Med Quad. https://t.co/uOJiL13B18

[Michal Sheffer @MichalSheffer]

@LabWaggoner @romeerizwan @Roma_Shap @HeadNeckMD Thank you for highlighting our work!

[Michal Sheffer @MichalSheffer]

@RemyDulery @Roma_Shap @romeerizwan Thank you Rémy!

[Michal Sheffer @MichalSheffer]

@YLeyfman @romeerizwan @HeadNeckMD Thank you 🙏

[Michal Sheffer @MichalSheffer]

Thrilled to share our paper, "First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer".
A big thank you to Roman Shapiro, Rizwan Romee @romeerizwan, Glen Hanna @HeadNeckMD and all co-authors.

[Michal Sheffer @MichalSheffer]

6/6 This study highlights the important considerations for the design of future clinical trials combining cellular therapy with checkpoint inhibition and the complexity of this combination.

[Michal Sheffer @MichalSheffer]

5/6 and activation. On the other hand, ipilimumab was associated with reduced donor NK cell persistence, suggesting that this was mediated by the rapid recovery of CD8+ T cells, rejecting the donor cells via HLA mismatch

[Michal Sheffer @MichalSheffer]

@JayantYGadrey6 @romeerizwan @HeadNeckMD Thank you 🙏

[Michal Sheffer @MichalSheffer]

Today we heard about the great work presented by @JohnSunwooMD
Very impressive!

[Rizwan Romee @romeerizwan]

It was great to host and hear about impressive work on ilc-like NK cells by ⁦@JohnSunwooMD⁩ from ⁦@Stanford⁩ today ⁦⁦@DanaFarberNews⁩ ⁦@DrUppaluri ⁦@HeadNeckMD ⁦@Roma_Shap⁩ @MichalSheffer⁩ #romeelab #NK cells

[Rizwan Romee @romeerizwan]

Promising mem-like NK cell study led by @Roma_Shap in MRD+ and or TP53mut AML undergoing RIC HCT..addressing a major unmet need. https://t.co/iO4nEnQWGJ

[Michal Sheffer @MichalSheffer]

Good luck Isabel and Linh!

[Rizwan Romee @romeerizwan]

Incredibly proud of Linh and Isabel who worked as research assistants in the lab and now soon starting their graduate school at Brown and BU. #romeelab ⁦@MichalSheffer⁩

[Michal Sheffer @MichalSheffer]

Great food and amazing people at the Romee lab’s picnic today
Good luck to Isabel and Dihn in their PhD studies

[Rizwan Romee @romeerizwan]

Had a wonderful time at our summer lab picnic today #romeelab ⁦@MichalSheffer⁩ ⁦@RemyDulery⁩ ⁦@graceandscience⁩ ⁦@DanaFarber⁩